AI Summary
This article discusses the engineering and characterization of a long-half-life relaxin receptor RXFP1 agonist. The research focuses on developing a new compound that can activate the relaxin receptor RXFP1 for a longer duration. This could have implications for drug development in the field of relaxin signaling and potential therapeutic applications.
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.4c00368